B-MoGen Biotechnologies Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
20
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$55.5M
- Investors
-
1
B-MoGen Biotechnologies General Information
Description
Developer of a genome engineering technology designed for gene delivery and gene editing. The company's technology offers custom vector generation services, which include multi-gene expression vectors are delivered via the proven Sleeping Beauty transposon system and transposase vectors to create unique research services and disease models in cells, enabling scientists to create life-changing medicines for human disease that are less expensive and more efficient.
Contact Information
Website
www.bmogen.comCorporate Office
- 1621 East Hennepin Avenue
- Suite B-15
- Minneapolis, MN 55414
- United States
Corporate Office
- 1621 East Hennepin Avenue
- Suite B-15
- Minneapolis, MN 55414
- United States
B-MoGen Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 04-Jun-2019 | $55.5M | Completed | Generating Revenue | ||
| 7. Grant | 08-Aug-2018 | Completed | Generating Revenue | |||
| 6. Grant | 06-Aug-2018 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series A1) | 08-Jun-2018 | Completed | Generating Revenue | |||
| 4. Grant | 01-Jan-2018 | Completed | Generating Revenue | |||
| 3. Grant | 01-Jan-2017 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 16-May-2016 | $1.5M | $1.5M | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2015 | Completed | Startup |
B-MoGen Biotechnologies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | ||||||||
| Series A |
B-MoGen Biotechnologies Comparisons
Industry
Financing
Details
B-MoGen Biotechnologies Competitors (78)
One of B-MoGen Biotechnologies’s 78 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| ERS Genomics | Corporate Backed or Acquired | Dublin, Ireland | ||||
| ToolGen | Formerly VC-backed | Seoul, South Korea | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| MeiraGTx | Formerly VC-backed | New York, NY |
B-MoGen Biotechnologies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
B-MoGen Biotechnologies Patents
B-MoGen Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2021247989-A1 | Enhanced hat family member spin transposon-mediated gene transfer and associated compositions, systems, and methods | Inactive | 05-Jun-2020 | ||
| CA-3104288-A1 | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods | Pending | 21-Jun-2018 | ||
| JP-2024041866-A | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods | Active | 21-Jun-2018 | ||
| WO-2019246486-A2 | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods | Inactive | 21-Jun-2018 | ||
| CA-3047313-A1 | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods | Pending | 16-Dec-2016 | C12N9/12 |
B-MoGen Biotechnologies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
B-MoGen Biotechnologies Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 701 Fund | Angel Group | Minority | ||
| Lateral Frontiers VC | Venture Capital | Minority | ||
| Mayo Clinic Ventures | Corporate Venture Capital | Minority | ||
| NIH Office of the Director | Government | |||
| National Heart, Lung, and Blood Institute | Government |
B-MoGen Biotechnologies FAQs
-
When was B-MoGen Biotechnologies founded?
B-MoGen Biotechnologies was founded in 2015.
-
Where is B-MoGen Biotechnologies headquartered?
B-MoGen Biotechnologies is headquartered in Minneapolis, MN.
-
What is the size of B-MoGen Biotechnologies?
B-MoGen Biotechnologies has 20 total employees.
-
What industry is B-MoGen Biotechnologies in?
B-MoGen Biotechnologies’s primary industry is Biotechnology.
-
Is B-MoGen Biotechnologies a private or public company?
B-MoGen Biotechnologies is a Private company.
-
What is the current valuation of B-MoGen Biotechnologies?
The current valuation of B-MoGen Biotechnologies is .
-
What is B-MoGen Biotechnologies’s current revenue?
The current revenue for B-MoGen Biotechnologies is .
-
How much funding has B-MoGen Biotechnologies raised over time?
B-MoGen Biotechnologies has raised $3.7M.
-
Who are B-MoGen Biotechnologies’s investors?
701 Fund, Lateral Frontiers VC, Mayo Clinic Ventures, NIH Office of the Director, and National Heart, Lung, and Blood Institute are 5 of 11 investors who have invested in B-MoGen Biotechnologies.
-
Who are B-MoGen Biotechnologies’s competitors?
Regenxbio, ERS Genomics, ToolGen, Genetix Biotherapeutics, and MeiraGTx are some of the 78 competitors of B-MoGen Biotechnologies.
-
When was B-MoGen Biotechnologies acquired?
B-MoGen Biotechnologies was acquired on 04-Jun-2019.
-
Who acquired B-MoGen Biotechnologies?
B-MoGen Biotechnologies was acquired by Bio-Techne.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
